GILD240719P55000
- 0.01
- -0.01-50.00%
Gilead Sciences Newsroom
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Gilead Sciences's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78
Gilead Sciences (GILD) has an average rating of outperform and price targets ranging from $67 to $119, according to analysts by Capital IQ.Price: 69.00, Change: +0.25, Percent Change: +0.36
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Hold Rating, Cuts Target Price to $74
Morgan Stanley analyst Terence Flynn maintains $Gilead Sciences(GILD.US)$ with a hold rating, and adjusts the target price from $78 to $74.According to TipRanks data, the analyst has a success rate
Pfizer Signals Progress on Obesity Pill, Boosting Stock
By Ciara Linnane and Eleanor Laise Oral versions of popular weight-loss drugs could be cheaper, more accessible, analysts say Pfizer Inc.'s stock (PFE) rose 2.8% early Thursday, after the drug
Is Gilead Sciences (NASDAQ:GILD) A Risky Investment?
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
Looking Into Gilead Sciences's Recent Short Interest
Gilead Sciences's (NYSE:GILD) short percent of float has fallen 25.98% since its last report. The company recently reported that it has 18.81 million shares sold short, which is 1.51% of all regular
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Barclays analyst Carter Gould maintains $Gilead Sciences(GILD.US)$ with a hold rating, and maintains the target price at $76.According to TipRanks data, the analyst has a success rate of 57.7% and a
Barclays Sticks to Its Hold Rating for Gilead Sciences (GILD)
Citi Research's AI Hedge Stocks - Part I
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,400 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.92% on an annualized basis producing an average annual return of 11.33%. Currently, Gilead Sciences has a market
Express News | Gilead : RBC Cuts Target Price to $71 From $74
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
Today's Morning Movers and Top Ratings: TSLA, PNC, SEDG, GLW and More
PNC Financial Services shares gained 1.21% upon receiving an upgrade by UBS to buy from neutral, with UBS citing the regional bank's potential for growth as loan demand shows signs of improvement.
Ideaya Stock Jumps After Positive Study Data From Cancer Study
Express News | Gilead Sciences Shares up 2.6% Premarket After Raymond James Raises to Outperform From Market Perform
Express News | Gilead : Raymond James Raises to Outperform From Market Perform
Express News | Gilead Sciences Shares Are Trading Higher After Raymond James Upgraded the Stock From Market Perform to Outperform